This retrospective analysis, including 321 patients, represents to the best of our knowledge the largest cohort to date assessing the efficiency of PSMA-targeted PET/CT in detecting biochemical recurrence (BCR) of prostate cancer with very low PSA levels ≤ 0.2 ng/mL. The gene discussed is FOLH1; the disease is prostate carcinoma.